Laia Crespo, PhD MBA
Laia is Investment Director in Ysios Capital. She has been Board Observer at AM-Pharma and currently serves on the board of OxThera (Stockholm), Minoryx Therapeutics (Barcelona) and Inbiomotion (Barcelona). Prior to joining Ysios she assessed commercial and scientific license opportunities as part of the European New Business Development team of Janssen-Cilag, a pharmaceutical company of the Johnson & Johnson group.
Laia developed her professional career primarily in the biotechnology cluster of Cambridge, UK, in companies such as Spirogen (now AstraZeneca), Medivir and UCB-Celltech. She holds a PhD in Chemistry from the University of Barcelona and an MBA from Cambridge Judge Business School, University of Cambridge.”